Lamivir (Lamivudine)

✅ Key Benefits

• Effective suppression of HIV‑1 reverse transcriptase activity

• Supports immune health and reduces viral load

• Low pill burden and minimal side effects for many patients

• Proven component in dual/triple ART regimens

• Approved for adult and pediatric use (per dosing guidelines)

🎯 How to Use

• Adults: 300 mg once daily or 150 mg twice daily as prescribed

• Pediatric dosing: weight-based per clinical guidelines

• Can be taken with or without food; maintain consistent schedule

• Regular monitoring of viral load and CD4 count is essential

• Swallow whole; do not crush or chew

• Store in a cool, dry place out of direct sunlight

⚠️ Precautions

• Prescription-only therapy; use under clinician oversight

• Monitor for hematologic changes, liver and renal function

• Use with caution if pregnant or breastfeeding after benefit–risk evaluation

• Do not discontinue abruptly; consult provider if symptoms worsen

• Seek medical attention if rash, unexplained fatigue, or GI distress occur

🤕 Possible Side Effects

• Common: Nausea, fatigue, headache, diarrhea

• Occasional: Elevated liver enzymes, neutropenia or anemia

• Rare but serious: Lactic acidosis, severe anemia, hypersensitivity—seek urgent medical care if present

🎁 The Medicine Villa Special Offers

• 🏷️ Flat 50% OFF – Use Coupon Code: TMV50

• 🚚 Free USA Shipping on orders over $199

• 📦 USA to USA Delivery in 3–4 Days for eligible products

• 🔒 Secure Checkout & Discreet Medical Packaging

❓ Frequently Asked Questions (FAQs)

Q. What is Lamivir used for?
A. It is used to suppress HIV‑1 replication as part of combined antiretroviral therapy regimens.

Q. How often is it taken?
A. Typically once daily (300 mg) or twice daily (150 mg), depending on regimen and patient needs.

Q. Are lab tests needed during treatment?
A. Yes—monitor viral load, CD4 count, and blood counts periodically.

Q. Can it be used by children?
A. Yes—pediatric dosing is available when used in appropriate combinations under medical supervision.